MARKET

TNXP

TNXP

Tonix
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.6018
+0.0003
+0.05%
Opening 10:32 09/23 EDT
OPEN
0.6087
PREV CLOSE
0.6015
HIGH
0.6100
LOW
0.5950
VOLUME
2.30M
TURNOVER
--
52 WEEK HIGH
2.120
52 WEEK LOW
0.5100
MARKET CAP
215.16M
P/E (TTM)
-1.7695
1D
5D
1M
3M
1Y
5Y
BRIEF-Tonix Expands Research Collaboration To Develop Precision Medicine Techniques For COVID-19 Vaccines
reuters.com · 3h ago
Tonix Pharmaceuticals to Present at the Cantor Virtual Global Healthcare Conference
CHATHAM, N.J., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Toni...
GlobeNewswire · 1d ago
For COVID-19, Live Virus Vaccines Could Give Longer Term Protection Than the Current Warp Speed Vaccines — But They're Not Here Yet
Photo by Diana Polekhina on Unsplash
Benzinga · 09/14 12:16
Tonix Pharma Expects to Start Early-Stage COVID-19 Vaccine Trial Next Year Following FDA Response
MT Newswires · 09/13 15:14
Tonix Pharma Shares FDA Response For COVID-19 Vaccine Candidate Human Study
Benzinga · 09/13 13:44
Tonix Pharmaceuticals Announces Results Of Pre-IND Meeting With FDA For TNX-1800 As A Potential Vaccine To Prevent COVID-19; Says Phase 1 Trial Expected To Start In 1H Of 2022
TNX-1800 is a Live Virus Vaccine Designed to Elicit Durable T cell Immunity   TNX-1800 is a Modified Version of Dr. Edward Jenner's Vaccine that Eradicated Smallpox, Engineered to Express SARS-CoV-2 Spike
Benzinga · 09/13 12:02
Tonix Pharmaceuticals Announces Results of Pre-IND Meeting with FDA for TNX-1800 as a Potential Vaccine to Prevent COVID-19
TNX-1800 is a Live Virus Vaccine Designed to Elicit Durable T cell Immunity TNX-1800 is a Modified Version of Dr. Edward Jenner’s Vaccine that Eradicated Smallpox, Engineered to Express SARS-CoV-2 Spike Protein In Animal Testing, TNX-1800 Protected Upper a...
GlobeNewswire · 09/13 12:00
Tonix Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will present at the H.C. Wainwright 23 Annual G...
GlobeNewswire · 09/07 11:00
More
Forecast
Actual (K USD)
Estimate (K USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TNXP. Analyze the recent business situations of Tonix through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TNXP stock price target is 3.750 with a high estimate of 4.500 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 97
Institutional Holdings: 74.73M
% Owned: 20.90%
Shares Outstanding: 357.52M
TypeInstitutionsShares
Increased
16
32.13M
New
35
6.08M
Decreased
12
2.11M
Sold Out
18
2.42M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.04%
Pharmaceuticals & Medical Research
+1.12%
Key Executives
Chairman/Chief Executive Officer/President/Director
Seth Lederman
Chief Financial Officer/Treasurer
Bradley Saenger
Chief Operating Officer
Jessica Morris
Secretary
Gregory Sullivan
Lead Director/Independent Director
James Treco
Director
Carolyn Taylor
Independent Director
Richard Bagger
Independent Director
Margaret Bell
Independent Director
Daniel Goodman
Independent Director
David Grange
Independent Director
Adeoye Olukotun
No Data
  • All
  • Financials
  • Insiders
More
About TNXP
Tonix Pharmaceuticals Holding Corp. is a clinical-stage pharmaceutical company. The Company's drug development programs are directed toward disorders affecting the central nervous system (CNS), and include fibromyalgia (FM), and post-traumatic stress disorder (PTSD). It is focused on developing a portfolio of product candidates, including one product candidate in clinical development for registration in two indications. TNX-102 SL (cyclobenzaprine hydrochloric acid (HCl) sublingual tablets), is a disintegrating tablet containing cyclobenzaprine (CBP) for sublingual administration. The Company has completed Phase IIb BESTFIT trial of TNX-102 SL for fibromyalgia. It is being evaluated in the Phase III AFFIRM study for the treatment of fibromyalgia. The Company is also conducting AtEase trial, which is a Phase II clinical trial of TNX-102 SL in military-related PTSD. It also has a pipeline of other product candidates, including TNX-301, a fixed dose combination drug product (CDP).

Webull offers kinds of Tonix Pharmaceuticals Holding Corp stock information, including NASDAQ:TNXP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TNXP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TNXP stock methods without spending real money on the virtual paper trading platform.